Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

NCT04095364 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT04095364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04095364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Lead sponsor
NRG Oncology
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 20, 2019
Completion date
February 1, 2028
Enrollment
450 (estimated)
Sites
909

Conditions

As the registry lists them; a condition with its own page is linked.

low grade fallopian tube serous adenocarcinoma, ovarian low grade serous adenocarcinoma, primary peritoneal low grade serous adenocarcinoma, stage ii fallopian tube cancer ajcc v8, stage ii ovarian cancer ajcc v8, stage ii primary peritoneal cancer ajcc v8, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8